Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

2018530 citationsJournal Articlebronze Open Access

Authors

Meletios Α. Dimopoulos · National and Kapodistrian University of Athens

Dominik Dytfeld · Poznan University of Medical Sciences

Sebastian Grosicki · Medical University of Silesia

Philippe Moreau

Naoki Takezako · National Disaster Medical Center

Mitsuo Hori · Ibaraki Prefectural Central Hospital

Xavier Leleu · Centre Hospitalier Universitaire de Poitiers

Abstract

Among patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor had failed, the risk of progression or death was significantly lower among those who received elotuzumab plus pomalidomide and dexamethasone than among those who received pomalidomide plus dexamethasone alone. (Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-3 ClinicalTrials.gov number, NCT02654132 .).

Topics & Keywords

Multiple Myeloma Research and Treatments Peptidase Inhibition and Analysis Ubiquitin and proteasome pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 379, Issue 19, pp. 1811-1822

DOI: 10.1056/nejmoa1805762

Field-Weighted Citation Impact: 46.63